CLDX
Celldex Therapeutics, Inc.
$39.63
Earnings Summary
Revenue | $4.13Mn |
Net Profits | $-43.31Mn |
Net Profit Margins | -1048.32% |
Highlights
Celldex Therapeutics, Inc.’s revenue jumped 156.11% since last year same period to $4.13Mn in the Q4 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 172.31% jump in its revenue since last 3-months.
Celldex Therapeutics, Inc.’s net profit fell -82.8% since last year same period to $-43.31Mn in the Q4 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -13.19% fall in its net profits since last 3-months.
Celldex Therapeutics, Inc.’s net profit margin jumped 28.63% since last year same period to -1048.32% in the Q4 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 58.43% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Celldex Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -0.69 |
EPS Estimate Current Year | -0.69 |
Highlights
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a 6.76% jump from last quarter’s estimates.
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.69.
Key Ratios
Key ratios of the Celldex Therapeutics, Inc. post its Q4 2023 earnings
Earning Per Share (EPS) | -0.83 |
Highlights
Celldex Therapeutics, Inc.’s earning per share (EPS) fell -48.21% since last year same period to -0.83 in the Q4 2023. This indicates that the Celldex Therapeutics, Inc. has generated -48.21% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-02-26 | -0.74 | -0.83 | -12.16% |
2023-08-08 | -0.67 | -0.65 | 2.99% |
2023-05-04 | -0.63 | -0.62 | 1.59% |
2023-11-02 | -0.68 | -0.81 | -19.12% |
₹0 US Stocks a/c Opening Fee